OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference PR Newswire BOTHELL, WA and VANCOUVER, March 28, 2013 BOTHELL, WA and VANCOUVER, March 28, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York City. A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website atwww.oncogenex.com. The webcast replay will be archived for 60 days. About OncoGenex OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com . SOURCE OncoGenex Pharmaceuticals, Inc. Contact: Media Contact: Jaime Welch email@example.com 604-630-5403 Investor Relations Contact: Susan Specht firstname.lastname@example.org 425-686-1535
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
Press spacebar to pause and continue. Press esc to stop.